Virax signs supply deal with US MedImmune
02 April, 2003 by Melissa TrudingerVirax Holdings has entered into a supply agreement with US biotechnology company MedImmune.
Prana tackles Parkinson's disease
31 March, 2003 by Melissa TrudingerA paper published in prestigious journal Neuron has heralded Prana Biotechnology's technology as a potential therapeutic for Parkinson's disease and revealed the company's strategy to develop its MPAC (metal protein attenuating protein) class of compounds as a platform technology for a variety of diseases.
Eiffel targeting big pharma in 'low risk' strategy
28 March, 2003 by Jeremy TorrWhen Eiffel Technologies' CEO Christine Cussen said last December that the company would start this year with $6.2 million in its back pocket, she outlined several ways the funds would be used. One of these -- pursuing drug re-engineering research to extend patent protection -- could prove particularly lucrative given that drugs worth more than $US42 billion will come off patent in the next three years.
QBF to make first investments
27 March, 2003 by Pete YoungThe Queensland BioCapital Fund (QBF) appears set to throw its considerable weight into the venture capital scene in the most practical way possible - by making its first investments.
Axon teams with Affymetrix to develop gene scanning system
27 March, 2003 by Pete YoungDrug discovery instrumentation company Axon Instruments is joining forces with genomics tools supplier Affymetrix to develop a new type of gene scanning system that could deliver a much-needed revenue boost to Axon.
Melbourne Uni report positive on GM canola varieties
26 March, 2003 by Graeme O'NeillA new report from the University of Melbourne has found that genetically modified (GM), herbicide-tolerant canola varieties could be worth up to $AUD135 million a year to Australia's canola and wheat industries.
WA centre gets new SNP detection equipment
26 March, 2003 by Jeremy TorrIn a major boost for the WA State Agricultural Biotechnology Centre (SABC) at Murdoch University, researchers will take delivery of a new Transgenomic WAVE Denaturing High Performance Liquid Chromatograph (DHPLC).
Antisense defended in wake of Isis trial failure
25 March, 2003 by Melissa TrudingerMark Diamond, the CEO of Australian company Antisense Therapeutics, has defended antisense technology in the wake of a failed trial of the technology by US companies Isis Pharmaceuticals and Eli Lilly.
Big names scheduled to speak at NSW careers night
25 March, 2003 by Iain ScottAusBiotech's NSW branch has assembled a high-profile line-up for a careers night this Wednesday March 26.
CEO Shaw to leave Ambri
24 March, 2003 by Iain ScottDr Joe Shaw, the managing director and CEO of Sydney-based biosensor specialist Ambri (ASX: ABI), has resigned from the company and will return to the US.
Revamped Start grants boosting biotechs
21 March, 2003 by Pete YoungBiotech companies are shouldering their way into the first wave of successful applicants to the Federal Government’s re-launched R&D Start grant program, supporting research efforts with commercial potential.
Australia chosen for drug firm's regional hub
21 March, 2003 by Jeremy TorrDrug firm Bristol-Myers Squibb has listed its Melbourne R&D facility at Noble Park as one of 14 global hubs for clinical research and development. The only other hub in the region is Singapore, with others in the US, Europe and Latin America.
Autogen becomes AGT Biosciences
20 March, 2003 by Melissa TrudingerAs the final step in a process of transformation that has taken almost a year, Victorian gene discovery company Autogen (ASX: AGT) has rebadged itself as AGT Biosciences.
Promics feeling optimistic after trials
20 March, 2003 by Pete YoungBrisbane biotech Promics is feeling optimistic after successfully concluding human toxicity and safety trials on its anti-inflammatory drug PMX 53.
Brain Resource Company signs with IBM
19 March, 2003 by Jeremy TorrSydney-based Brain Resource Company (BRC) has signed a business partner deal with IBM to tie up its innovative Integ Neuro series of cognitive performance tests to IBM's integrated Countertop kiosk input devices.
